Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey

Transplantation

Volumn 69, Issue 7, 2000, Pages 1275-1283

  Qi, Shijie ^a   Xu, Dasheng ^a   Peng, Junzheng ^a   Vu, Minh Diem ^a   Wu, Jiangping ^b   Bekersky, Ihor ^c,d   Fitzsimmons, William E ^c,d   Peets, Jaan ^c,d   Sehgal, Suren ^e   Daloze, Pierre ^a   Chen, Huifang ^a,f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d Fujisawa Canada Inc   (Canada)

^e PFIZER INC   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HISTOPATHOLOGY; KIDNEY ALLOGRAFT; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 18244423842     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00012     Document Type: Article

References (65)

1. Kino T, Hatanaka H, Hashimoto M, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation and physiochemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249.
2. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256.
3. Zeevi A, Duquesnoy R, Eiras G, et al. Immunosuppressive effect of FK506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc 1987; 19(suppl 6): 40.
4. Inamura N, Hashimoto M, Nakahara K, et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988; 46: 82.
5. Inamura N, Nakahara K, Kino T, et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 1988; 45: 206.
6. Lim S, Thiru S, White DJG. Heterotopic heart transplantation in the rat receiving FK506. Transplant Proc 1987; 19(suppl 6): 68.
7. Murase N, Todo S, Lee P-H, et al. Heterotopic heart transplantation in the rat receiving FK506 alone or with cyclosporine. Transplant Proc 1987; 19(suppl 6): 71.
8. Ochiai T, Nakajima K, Nagata M, et al. Studies on the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation 1987; 44: 734.
9. Collier DStJ, Thiru S, Calne RY. Kidney transplantation in the dog receiving FK506. Transplant Proc 1987; 19(suppl 6): 62.
10. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729.
11. Todo S, Podesta L, Chapchap P, et al. Orthotopic liver transplantation in dogs receiving FK506. Transplant Proc 1987; 19(suppl 6): 64.
12. Calne RY, Collier DStJ, Thiru S. Observations about FK506 in primates. Transplant Proc 1987; 19(suppl 6): 63.
13. Imventarza O, Todo S, Eiras G, et al. Renal transplantation in baboons under FK506. Transplant Proc 1990; 22(suppl 1): 64.
14. Todo S, Fung J, Demetris AJ, et al. Early trials with FK506 as primary treatment in liver transplantation. Transplant Proc 1990; 22: 13.
15. Starzel TE, Todo S, Fung J, et al. FK506 for liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000.
16. Metcalf SM, Richards FM. Cyclosporine, FK506, and rapamycin. Transplantation 1990; 49: 798.
17. Sigal NH, Dumont FJ. Cyclosporine A, FK506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519.
18. Vezina C, Kudelski A, Sehgal S. Rapamycin (AY-22-989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of active principle. J Antibiot 1975; 28: 721.
19. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22-989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot 1875; 28: 727.
20. Molnar-Kimber KL. Mechanism of action of rapamycin (sirolimus, rapamycin). Transplant Proc 1996; 28: 964.
21. Sehgal SN: Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
22. Calne RY, Collier DstJ, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
23. Morris RE, Meiser M. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609.
24. Stepkowski SH, Chen H, Daloze P, Kahan B. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel allografts. Transplantation 1991; 52: 22.
25. Chen H, Wu J, Luo HY, Daloze P. The immunosuppressive effect of rapamycin on pancreaticoduodenal transplantation in the rat. Transplant Proc 1991; 23: 2239.
26. Chen H, Wu J, Luo H, Daloze P. Reversal of ongoing rejection of allograft by rapamycin. Transplant Proc 1991; 23: 2241.
27. Chen H, Wu J, Xu D, Luo H, Daloze P. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 661.
28. Luo H, Chen H, Daloze P, Chang J, Wu J. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 1992; 53: 1071.
29. Chen H, Luo H, Daloze P, et al. Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat. Immunobiology 1993; 188: 303.
30. Chen H, Wu J, Xu D, Aboujaoude M, Daloze P. The effect of rapamycin on orthotopic small bowel transplantation in the rat. Transplant Proc 1992; 24: 1157.
31. Chen H, Qi S, Xu D, Wu J, Daloze P. The immunosuppressive effect of rapamycin on mouse small bowel transplantation. Transplantation 1996; 61: 523.
32. Chen H, Luo H, Daloze P, Xu D, Wu J Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J Immunol 1994; 152: 3107.
33. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PL, Sigal NA. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
34. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin. J Exp Med 1992; 176: 751.
35. Chen H, Qi S, Xu D, et al. FK506 and rapamycin in combination are not antagonistic but produce extended small bowel survival in the mouse. Transplant Proc 1998; 30: 1039.
36. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
37. Solez K, Axelson RA, Bendiktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
38. Chou TC. The median-effect principle and combination index for quantitation of synergism and antagonism. In: Chou TC, Ride-out D, eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991: 61.
39. Stepkowski SH, Napoli KL, Wang ME, Qu X, Chou TC, Kahan BD. Effect of the pharmacokinetic interaction between orally administered sirolimus and cyclosporin on the synergistic prolongation of heart allograft survival in the rat. Transplantation 1996; 62: 986.
40. Kelly PA, Gruber SA, Behbod F, Kahan B. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17: 1148.
41. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Benneth WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 1994; 57: 483.
42. Bierer BE, Somers PK, Wandless TJ, Burakoff ST, Schreiber SL. Probing immunosuppressants action with nonnatural immunophilin ligand. Science 1990; 250: 56.
43. Yakimeta WJ, Lakey JRT, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporin therapy at low doses. Transplantation 1994; 56: 1293.
44. Bumgardner GL, Robert JP. New immunosuppressive agents. Adv Liver Transplant 1993; 22: 421.
45. Hirano Y, Fujihara S, Ohara K, et al. Morphological and functional changes in islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
46. Tze WJ, Tai J, Murase N, et al. Effect of FK506 on glucose metabolism and insulin secretion in rats. Transplant Proc 1991; 23: 3158.
47. Ericzson BG, Wijnen RMH, Kobota K, et al. FK506-induced impairment of glucose metabolism in the primate: studies in pancreatic transplant recipients and in non-transplanted animals. Transplantation 1992; 54: 615.
48. Carrol PB, Boschero AC, Li MY, et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation 1991; 51: 275.
49. Ohara K, Billington R, James RW, et al. Toxicologic evaluation of FK506. Transplant Proc 1990; 22: 83.
50. Thiru S, Collier DStJ, Calne R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK506. Transplant Proc 1987; 19: 98.
51. Bennett WM, Burdmnn E, Andoh T, et al. Nephrotoxicity of immunosuppressive drugs. Miner Electrolyte Metab 1994; 20: 214.
52. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63: 374.
53. Cosimi AB, Burton RC, Kung PC, et al. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc 1981; 13: 499.
54. 4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation 1985; 39: 247.
55. + T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin. J Immunol 1987; 138: 164.
56. Wright JK, Barrett LV, Delmonico FL, Fuller TC, Cosimi AB. Preclinical evaluation of immunosuppression selective for T cells recognizing class I histocompatibility antigens. Transplant Proc 1987; 19: 1106.
57. Nocera A, Barocci S, Valente U, et al. In vitro characterization of a donor-specific cytolytic T cell line established from human lymphocytes homing in rejected kidney allografts. Transplantation 1986; 41: 135.
58. Charpentier BM, Bach M, Lang P, Martin B, Fries D. Phenotypic composition and in vitro functional capacities of unmodified fresh cells infiltrating acutely rejected human renal allografts. Transplantation 1987; 44: 38.
59. Dallman MJ, Shiho O, Page TH, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
60. Noronha IL, Eberlein-Gonska M, Hartley B, et al. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in renal allograft biopsy. Transplantation 1992; 54: 1017.
61. Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992; 54: 326.
62. Cunningham DA, Dunn MJ, Yacoub MH, Rose ML. Local production of cytokines in the human cardiac allograft. Transplantation 1994; 57: 1333.
63. McAlister V, Peltekian K, Mahalati K, Gao Z, Dominquez J, MacDonald A. Sirolimus tacrolimus combination immunosuppression. Annual Scientific Meeting of Canadian Society of Transplantation & Canadian Association of Transplantation. March 3-6, 1999. Lake Louise, Alberta, Abstract Book, p. 52.
64. De Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G. FK506, a potent novel inhibitor of the release of proinflammatory mediators from human FceRI + cells. J Immunol 1991; 146: 2374.
65. Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55: 423.